Latest DiaSorin News & Updates

See the latest news and media coverage for DiaSorin. We track all announcements, press releases, and industry mentions in real time, all in one place.

DiaSorin

Immunodiagnostics, molecular diagnostics, and licensed technology company

int.diasorin.com

Headquarters: Saluggia, Italy
Company type: Public company
Number of employees: 2,900–5,000
Industry: Advanced Medical Equipment & Technology

Last updated October 21

Latest news about DiaSorin

In short: Diasorin received FDA approvals for new tests and reported mixed H1 2026 results amid US expansion.

Company announcements

October 13 DiaSorin

Diasorin receives FDA approval for automated Parvovirus B19 tests

The LIAISON XL assays provide same-day results to enable faster diagnosis and timely patient guidance for at-risk groups. These are available in the US.

July 31 DiaSorin

Diasorin's H1 2026 revenue and EBITDA supported by strong Q2 growth

Revenue was €602 million, flat at CER, with adjusted EBITDA of €194 million (32% margin). 2026 guidance confirmed.

June 19 DiaSorin

Diasorin receives FDA clearance and CLIA waiver for GAS assay

The assay runs on the LIAISON NES POC platform and delivers molecular results in 15 minutes.

May 20 DiaSorin

Diasorin approves 2026-2030 business plan

The plan targets 4-6% CAGR revenue growth and 34-35% EBITDA margin by 2030, focusing on specialty diagnostics expansion.

Media coverage

October 21 FTA Online

Diasorin on the attack of important resistances: OPA Qiagen and positive analysts on trim3

Diasorin moves against the market trend and at mid-morning is up +1.6% at 79.38 euros. The group's diagnostic stock takes advantage of the acquisition...

October 13 Il Sole 24 Ore

Diasorin: FDA approves rapid serological tests for Parvovirus

(Il Sole 24 Ore Radiocor) - Milan, Oct 13 - Diasorin has received approval from the U.S. Food and Drug Administration (FDA) for the first...

October 8 Torino Cronaca

From Piedmont to conquering the USA: DiaSorin's breakthrough on the virus that frightens mothers

Green light from the US FDA for the new rapid tests for Parvovirus, responsible for "fifth disease". The diagnostic excellence of Saluggia beats everyone on time and brings...

September 30 Ad Hoc News

DiaSorin stock: management reaffirmed its 2026 outlook in July earnings call

DiaSorin management reaffirmed its 2026 outlook during a July earnings call. The discussion covered first-half performance and a return to growth in the second quarter...

Never miss news about DiaSorin

Track DiaSorin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

DiaSorin competitors & trending companies

Browse news for competitors to DiaSorin and other trending companies.